SF3B1 and cancer: Given the preferential dependence on splicing function in MDS-associated cells with RNA splicing factor mutations and the progressively more prominent pathogenic role of SF3B1 spliceosomal mutations in MDS and cancer, interest in the pharmacology of targeted splicing has been stimulated.